Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial

 Once-weekly intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported during treatment

https://www.streetinsider.com/Globe+Newswire/Bioxytran+Reports+Encouraging+Clinical+Observations+in+First+Chronic+Inflammatory+Demyelinating+Polyneuropathy+%28CIDP%29+Patient+Treated+with+PLICID%2C+a+Novel+Galectin+Antagonist+Designed+with+Artificial/26901027.html